
Europe Heparin Market, By Product Type (Low Molecular Weight Heparin, Unfractionated Heparin, Ultra Low Molecular Weight Heparin), By End User (Hospitals, Blood and Stem Cell Bank, Others (Laboratories, Acute Care Centers)), and By Region (North America,
Description
Europe Heparin Market, By Product Type (Low Molecular Weight Heparin, Unfractionated Heparin, Ultra Low Molecular Weight Heparin), By End User (Hospitals, Blood and Stem Cell Bank, Others (Laboratories, Acute Care Centers)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa ) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Heparin is obtained naturally from mucosal tissues of slaughtered meat animals such as porcine intestines or bovine lungs or prepared synthetically. It is also known as unfractionated heparin (UFH) and is used as an anticoagulant for treating acute coronary syndrome, atrial fibrillation (AF), venous thromboembolism (VTE), etc. Increasing prevalence of atrial fibrillation in developed and developing economies along with increasing research and development activities is anticipated to drive the market growth during the forecast period. Moreover, major players in the market are also focused on assessing the efficacy of heparin alternatives in the treatment which in turn is also expected to assist the market growth.
Key features of the study:
This report provides in-depth analysis of the Europe Heparin market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the Europe Heparin market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., GlaxoSmithKline plc, Bayer AG, Anselm Pharmaceuticals, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., Sanofi S.A., Syntex S.A., LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., United Biotech (P) Ltd, Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The Europe Heparin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe Heparin market
Detailed Segmentation:
Europe Heparin Market, By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
Europe Heparin Market, By End User:
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
Europe Heparin Market, By Region:
North America
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
U.S.
Canada
Latin America
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
U.K.
Germany
France
Spain
Italy
Russia
Rest of Europe
Asia Pacific
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
China
Japan
India
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
GCC Countries
Israel
Rest of Middle East
Africa
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
North Africa
Central Africa
South Africa
Company Profiles
Pfizer, Inc. *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Sagent Pharmaceuticals, Inc.
B. Braun Melsungen AG
Baxter International Inc.
GlaxoSmithKline plc
Bayer AG
Anselm Pharmaceuticals
Bristol-Myers Squibb Co.
Dr. Reddy’s Laboratories Ltd.
Fresenius SE & Co. KGaA
Leap Labchem Co.
LEO Pharma A/S
Sanofi S.A.
Syntex S.A.
Teva Pharmaceutical Industries Ltd.
United Biotech (P) Ltd
Amphastar Pharmaceuticals Inc.
Abbott Laboratories
Aspen Pharmacare Holdings
Laboratorios Farmaceuticos ROVI SA
Intrapharm Laboratories
“*” marked represents similar segmentation in other categories in the respective section.
Heparin is obtained naturally from mucosal tissues of slaughtered meat animals such as porcine intestines or bovine lungs or prepared synthetically. It is also known as unfractionated heparin (UFH) and is used as an anticoagulant for treating acute coronary syndrome, atrial fibrillation (AF), venous thromboembolism (VTE), etc. Increasing prevalence of atrial fibrillation in developed and developing economies along with increasing research and development activities is anticipated to drive the market growth during the forecast period. Moreover, major players in the market are also focused on assessing the efficacy of heparin alternatives in the treatment which in turn is also expected to assist the market growth.
Key features of the study:
This report provides in-depth analysis of the Europe Heparin market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the Europe Heparin market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., GlaxoSmithKline plc, Bayer AG, Anselm Pharmaceuticals, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., Sanofi S.A., Syntex S.A., LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., United Biotech (P) Ltd, Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The Europe Heparin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe Heparin market
Detailed Segmentation:
Europe Heparin Market, By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
Europe Heparin Market, By End User:
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
Europe Heparin Market, By Region:
North America
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
U.S.
Canada
Latin America
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
U.K.
Germany
France
Spain
Italy
Russia
Rest of Europe
Asia Pacific
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
China
Japan
India
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
GCC Countries
Israel
Rest of Middle East
Africa
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
North Africa
Central Africa
South Africa
Company Profiles
Pfizer, Inc. *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Sagent Pharmaceuticals, Inc.
B. Braun Melsungen AG
Baxter International Inc.
GlaxoSmithKline plc
Bayer AG
Anselm Pharmaceuticals
Bristol-Myers Squibb Co.
Dr. Reddy’s Laboratories Ltd.
Fresenius SE & Co. KGaA
Leap Labchem Co.
LEO Pharma A/S
Sanofi S.A.
Syntex S.A.
Teva Pharmaceutical Industries Ltd.
United Biotech (P) Ltd
Amphastar Pharmaceuticals Inc.
Abbott Laboratories
Aspen Pharmacare Holdings
Laboratorios Farmaceuticos ROVI SA
Intrapharm Laboratories
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
160 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By End User
- Market Snippet, By Country
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Highlights
- Product launch
- PEST Analysis
- Technological Advancements
- Regulatory Scenario
- Mergers and Acquisitions
- Impact of COVID19 on the market
- 4. Europe Heparin Market, By Product Type, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Low Molecular Weight Heparin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Unfractionated Heparin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Ultra Low Molecular Weight Heparin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 5. Europe Heparin Market, By End User, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Blood and Stem Cell Bank
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Others (Laboratories, Acute Care Centers)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 6. Europe Heparin Market, By Region, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
- North America
- Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Germany
- U.K.
- France
- Spain
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- China
- Japan
- India
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- North Africa
- Central Africa
- South Africa
- 7. Competitive Landscape
- Company Profiles
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sagent Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- B. Braun Melsungen AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Baxter International Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Anselm Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol-Myers Squibb Co.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Dr. Reddy’s Laboratories Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Fresenius SE & Co. KGaA
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Leap Labchem Co.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- LEO Pharma A/S
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Syntex S.A.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- United Biotech (P) Ltd
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Amphastar Pharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Abbott Laboratories
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Aspen Pharmacare Holdings
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Laboratorios Farmaceuticos ROVI SA
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Intrapharm Laboratories
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- 8. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 22 market data tables and 14 figures on “Heparin Market - Europe forecast to 2028”.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.